bioAffinity Technologies (BIAFW) EBT Margin (2022 - 2026)

bioAffinity Technologies has disclosed EBT Margin across 5 years of filings, most recently posting 268.63% for Q1 2026.

• In Q1 2026, EBT Margin fell 12557.0% year-over-year to 268.63%; the TTM figure through Mar 2026 stood at 279.95% (down 16959.0% YoY), while the FY2025 annual figure was 241.25%, down 14482.0% from the prior year.
• EBT Margin fell to 268.63% in Q1 2026, from 196.78% in the prior quarter.
• Over the last five years, EBT Margin for BIAFW reached as high as 81.37% in Q1 2024 and fell as low as 427752.87% in Q3 2022.
• The 5-year median for EBT Margin is 293.11% (2025), against an average of 42646.84%.
• The widest YoY moves for EBT Margin: up 42698613 bps in 2023, down 205101 bps in 2023.
• A 5-year view of EBT Margin shows it stood at 71380.39% in 2022, then surged by 100 bps to 107.12% in 2023, then slipped by 25 bps to 134.4% in 2024, then tumbled by 46 bps to 196.78% in 2025, then sank by 37 bps to 268.63% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 268.63%, 196.78%, and 349.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.